Latest Breaking News On - Independent scientific committee - Page 3 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic . Algernon PharmaceuticalsFebruary 1, 2021 GMT VANCOUVER, British Columbia, Feb. 01, 2021 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.

United statesUnited kingdomBritish columbiaSouth koreaCity ofChristopherj moreauEdmundj safraRick strassmanNeurosciences at merck research labsMaastricht universityNeurosciences instituteClinical development solutionsAmerican association for the advancement of scienceKorea institute of scienceNervous system drugs advisory committeeCompany or algernon